Influence of apolipoprotein E polymorphism on plasma vitamin A and vitamin E levels

European Journal of Clinical Investigation

Volumn 32, Issue 4, 2002, Pages 251-258

  Gómez Coronado, Diego ^a   Entrala, A ^a   Alvarez J J ^a,b   Ortega, H ^a   Olmos, J M ^a   Castro, M ^a   Sastre, A ^a   Herrera, E ^a,b   Lasuncion M A ^a,c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Apolipoprotein E polymorphism; Cholesterol; Triglyceride; Vitamin A; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL; TRIACYLGLYCEROL;

ANTHROPOMETRY; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIETARY INTAKE; DNA POLYMORPHISM; FEMALE; HUMAN; LIFESTYLE; LIPID ANALYSIS; MALE; MENOPAUSE; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; VITAMIN BLOOD LEVEL;

ADULT; APOLIPOPROTEINS E; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEX FACTORS; VITAMIN A; VITAMIN E;

EID: 0036995108     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.00983.x     Document Type: Article

References (61)

1. Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994;45:249-302.
2. Schächter F, Faure-Delanef L, Guénot F, Rouger H, Froguel P, Lesueur-Ginot L et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29-32.
3. Smith JD. Apolipoprotein E4: an allele associated with many diseases. Ann Med 2000;32:118-27.
4. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
5. Siest G, Pillot T, Régis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau M-M et al. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995;41:1068-86.
6. Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta 1999;286:115-43.
7. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apo E phenotype: a meta-analysis. J Lipid Res 1992;33:447-54.
8. Wilson PWF, Schaefer EJ, Larson MG, Ordovás JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-5.
9. Wilson PWF, Myers RH, Larson MG, Ordovás JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994;272:1666-71.
10. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaud et AL, Sly WS, Valle D, editors.The Metabolic and Molecular Bases of Inherited Disease 7th edn. New York: McGraw-Hill; 1995.p.1953-80.
11. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-4.
12. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995;92:4725-7.
13. Swartz RH, Black SE, St George-Hyslop P. Apolipoprotein E and Alzheimer's disease: a genetic, molecular and neuroimaging review. Can J Neurol Sci 1999;26:77-88.
14. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 1989;320:915-24.
15. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low-density lipoprotein hypothesis. Atherosclerosis 1998;141:1-15.
16. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994;77:817-27.
17. Butterfield DA, Howard B, Yatin S, Koppal T, Drake J, Hensley K, et al. Elevated oxidative stress in models of normal brain aging and Alzheimer's disease. Life Sci 1999;65:1883-92.
18. Clifton PM. Antioxidant vitamins and coronary heart disease risk. Curr Opin Lipidol 1995;6:20-4.
19. Kontush A, Spranger T, Reich A, Baum K, Beisiegel U. Lipophilic antioxidants in blood plasma as markers of atherosclerosis: the role of α-carotene and γ-tocopherol. Atherosclerosis 1999;144:117-22.
20. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
21. Yatin SM, Aksenov M, Butterfield DA. The antioxidant vitamin E modulates amyloid β peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochem Res 1999;24:427-35.
22. Gey KF, Puska P. Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann NY Acad Sci 1989;570:268-82.
23. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991;53:326S-34S.
24. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Cayley ACD. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing 1992;21:91-4.
25. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM 1999;92:39-45.
26. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR. Altered plasma oxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatr 1998;13:840-5.
27. Semba RD, Vitamin A, immunity and infection. Clin Infect Dis 1994;19:489-99.
28. Silveira ER, Moreno FS. Natural retinoids and β-carotene: from food to their actions on gene expression. J Nutr Biochem 1998;9:446-56.
29. Traber MG, Sies H. Vitamin E in humans: demand and delivery. Annu Rev Nutr 1996;16:321-47.
30. Brigelius-Flohé R, Traber MG. Vitamin E, function and metabolism. FASEB J 1999;13:1145-55.
31. Norum KR, Blomhoff R. McCollum award lecture 1992. Vitamin A absorption, transport, cellular uptake, and storage. Am J Clin Nutr 1992;56:735-44.
32. Demacker PNM, Hectors MPC, Stalenhoef AFH. Chylomicron processing in familial dysbetalipoproteinemia and familial combined hyperlipidemia studied with vitamin A and E as markers: a new physiological concept. Atherosclerosis 2000;149:169-80.
33. Hebert JR, Hurley TG, Hsieh J, Rogers E, Stoddard AM, Sorensen G, et al. Determinants of plasma vitamins and lipids: the Working Well Study. Am J Epidemiol 1994;140:132-47.
34. Jordan P, Brubacher D, Moser U, Stähelin HB, Gey KF. Vitamin E and vitamin A concentrations in plasma adjusted for cholesterol and triglycerides by multiple regression. Clin Chem 1995;41:924-7.
35. Vogel S, Contois JH, Tucker KL, Wilson PWF, Schaefer EJ, Lammi-Keefe CJ. Plasma retinol and plasma and lipoprotein tocopherol and carotenoid concentrations in healthy elderly participants of the Framingham Heart Study. Am J Clin Nutr 1997;66:950-8.
36. Gómez-Coronado D, Álvarez JJ, Entrala A, Olmos JM, Herrera E, Lasunción MA. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis 1999;147:167-76.
37. Frikke-Schmidt R. Context-dependent and invariant associations between APOE genotype and levels of lipoproteins and risk of ischemic heart disease: a review. Scand J Clin Lab Invest 2000;60 (Suppl. 233):3-26.
38. Entrala A, Lasunción MA, Olmos JM, Herrera E, Sastre A. Ingesta dietética y otros factores de riesgo cardiovascular en el personal laboral-sanitario del Hospital Ramón y Cajal. Nutrición Clínica 1990;10:7-26.
39. Souci SN, Fachmann W, Kraut H.Food Composition and Nutrition Tables. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH./90; 1989.
40. Gómez-Coronado D, Sáez GT, Lasunción MA, Herrera E. Different hydrolytic efficiencies of adipose tissue lipoprotein lipase on very low-density lipoprotein subfractions separated by heparin-Sepharose chromatography. Biochim Biophys Acta 1993;1167:70-8.
41. Cuesta Sanz D, Castro Santa-Cruz M. Simultaneous measurement of retinol and α-tocopherol in human serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1986;380:140-4.
42. Muros M, Rodríguez-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp (a) in a Spanish population underexpressing apo E4. Atherosclerosis 1996;121:13-21.
43. Herbeth B, Chavance M, Musse N, Mejean L, Vernhes G. Dietary intake and other determinants of blood vitamins in an elderly population. Eur J Clin Nutr 1989;43:175-86.
44. Ferro-Luzzi A, Mobarhan S, Maiani G, Scaccini C, Sette S, Nicastro A, et al. Habitual alcohol consumption and nutritional states in the elderly. Eur J Clin Nutr 1988;42:5-13.
45. Prasad AS, Oberleas D, Moghissi KS, Stryker JC, Lei KY. Effect of oral contraceptive agents on nutrients. II.Vitamins. Am J Clin Nutr 1975;28:385-91.
46. Vahlquist A, Johnsson A, Nygren KG. Vitamin A transporting plasma proteins and female sex hormones. Am J Clin Nutr 1979;32:1433-8.
47. Gleeson JM, Dukes CS, Elstad NL, Chan IF, Wilson DE. Effects of estrogen/progestin agents on plasma retinoids and chylomicron remnant metabolism. Contraception 1987;35:69-78.
48. Mooij PN, Thomas CM, Doesburg WH, Eskes TK. Multivitamin supplementation in oral contraceptive users. Contraception 1991;44:277-88.
49. Cundy T, Earnshaw M, Heynen G, Kanis JA. Vitamin A and hyperparathyroid bone disease in uremia. Am J Clin Nutr 1983;38:914-20.
50. Dicken CH. Elevation of blood triglyceride secondary to administration of vitamin A. Arch Dermatol 1981;117:189-90.
51. Murray JC, Gilgor RS, Lazarus GS. Serum triglyceride elevation following high-dose vitamin A treatment for pityriasis rubra pilaris. Arch Dermatol 1983;119:675-6.
52. Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985;313:981-5.
53. Jong MC, Hofker MH, Havekes LM. Role of apoCs in lipoprotein metabolism. Functional differences between apoC1, apoC2, and apoC3. Arterioscler Thromb Vasc Biol 1999;19:472-84.
54. Vu-Dac N, Gervois P, Pineda Torra I, Fruchart J-C, Kosykh V, Kooistra T, et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. J Clin Invest 1998;102:625-32.
55. Fruchart J-C, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999;10:245-57.
56. Pineda Torra I, Chinetti G, Duval C, Fruchar J-C, Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 2001;12:245-54.
57. Kliewer SA, Lehmann JM, Willson TM. Orphan nuclear receptors: shifting endocrinology into reverse. Science 1999;284:757-60.
58. Schoonjans K, Brendel C, Mangelsdorf D, Auwerx J. Sterols and gene expression: control of affluence. Biochim Biophys Acta 2000;1529:114-25.
59. Repa JJ, Turley SD, Lobaccaro J-MA, Medina J, Li L, Lustig K, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000;289:1524-9.
60. Kesaniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 1987;80:578-81.
61. Miettinen TA, Gylling H, Vanhanen H, Ollus A. Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apoprotein E phenotypes. Arterioscler Thromb 1992;12:1044-52.